Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-12Clinical Trial Update: Lifestyle MIND- Feasibility of Wait-list Control [NA]
A feasibility trial of a Lifestyle MIND intervention for individuals with Type 2 diabetes mellitus and serious mental illness (including sch…
-
CLINICAL_TRIALS withdrawal · 2026-01-28Clinical Trial Update: Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department [Phase 4]
A Phase 4 pilot trial of BXCL501 (sublingual dexmedetomidine) for agitation in the emergency department, including schizophrenia-spectrum an…
-
EMA withdrawal · 2025-09-23EMA Withdrawn: Olanzapine Apotex (olanzapine) — Apotex Europe BV
The EMA has withdrawn Olanzapine Apotex, an olanzapine product from Apotex Europe BV.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
ProgenaBiome's non-interventional pilot study investigating the role of gut flora in bipolar disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-04Clinical Trial Update: Sleep Quality, Cognitive Performance, and Computerized Cognitive Training
A clinical trial examining sleep quality, cognitive performance, and computerized cognitive training for bipolar disorder and major depressi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2022-10-14Clinical Trial Update: A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid [Phase 4]
A Phase 4 clinical trial investigating Ethyl Eicosapentaenoic Acid with [11C]PBR-28 in bipolar disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-02-21Clinical Trial Update: Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) [Phase 3]
A Phase 3 trial evaluating safety and tolerability of flexible doses of oral ziprasidone in children and adolescents with Bipolar I Disorder…
-
CLINICAL_TRIALS withdrawal · 2021-02-21Clinical Trial Update: Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196) [Phase 3]
A Phase 3 trial evaluating ziprasidone for bipolar I disorder in children and adolescents has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-02-21Clinical Trial Update: Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia [Phase 4]
A Phase 4 trial of suvorexant (Belsomra) for bipolar depression with insomnia has been withdrawn.
-
EMA withdrawal · 2020-10-22EMA Application withdrawn: Abilify MyCite (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.
The EMA has withdrawn the application for Abilify MyCite (aripiprazole) by Otsuka Pharmaceutical Netherlands B.V.
-
CLINICAL_TRIALS withdrawal · 2018-08-07Clinical Trial Update: Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar Disorder [Phase 2, Phase 3]
A clinical trial investigating deep brain stimulation for treatment-resistant bipolar disorder was withdrawn after Phase 2/3 planning.
-
CLINICAL_TRIALS withdrawal · 2018-07-20Clinical Trial Update: Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old [Phase 4]
Open-label Phase 4 study of lurasidone (Latuda) for mania in youths aged 6-17 was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine [NA]
A clinical trial investigating whether green tea can prevent olanzapine-associated weight gain and dyslipidemia in patients with bipolar dis…
-
CLINICAL_TRIALS withdrawal · 2018-02-09Clinical Trial Update: Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder [Phase 4]
A Phase 4 trial evaluating neural correlates for therapeutic mechanisms of lithium in bipolar disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder [Phase 2]
Phase 2 trial investigating a glutamate transporter GLT1 for bipolar disorder was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-02-17Clinical Trial Update: Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy [NA]
This clinical trial update reports the withdrawal of a Kaiser Permanente study evaluating ultrabrief right unilateral and brief-pulse electr…
-
CLINICAL_TRIALS withdrawal · 2016-05-24Clinical Trial Update: Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt
ClinicalTrials.gov entry reports the withdrawal of a study assessing neuropsychological characteristics of patients with bipolar disorder an…
-
CLINICAL_TRIALS withdrawal · 2016-05-17Clinical Trial Update: A Trial of Cognitive Training in Euthymic Bipolar Disorder [NA]
The trial 'A Trial of Cognitive Training in Euthymic Bipolar Disorder' sponsored by the University of Calgary has been withdrawn; no results…
-
EMA withdrawal · 2015-07-20EMA Application withdrawn: Aripiprazole Mylan (aripiprazole) — Generics (UK) Limited
The EMA report indicates withdrawal of the aripiprazole generic application from Generics (UK) Limited for schizophrenia and bipolar disorde…
-
CLINICAL_TRIALS withdrawal · 2015-06-01Clinical Trial Update: An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder [Phase 4]
Phase 4 trial evaluating divalproex versus olanzapine for preventing alcohol relapse in patients with bipolar disorder was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-05-08Clinical Trial Update: Identifying Predictors of Bipolar Disorder Relapse During Pregnancy and the Postpartum Period
Clinical trial update indicates that the NIMH study on predictors of bipolar disorder relapse during pregnancy and the postpartum period has…
-
CLINICAL_TRIALS withdrawal · 2015-04-28Clinical Trial Update: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder [Phase 2]
Phase 2 study evaluating the Medical Information Device #1 (MIND1) for adherence, safety, and tolerability in schizophrenia or Bipolar I dis…
-
CLINICAL_TRIALS withdrawal · 2015-03-31Clinical Trial Update: Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence [Phase 2]
A Phase 2 open-label trial of Depakote ER in patients with bipolar I/II depression and alcohol use disorder has been withdrawn from the stud…
-
CLINICAL_TRIALS withdrawal · 2014-11-21Clinical Trial Update: Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism [Phase 4]
Phase 4 trial of paliperidone palmitate for bipolar disorder complicated by alcoholism has been withdrawn.
-
EMA withdrawal · 2014-07-24EMA Withdrawn: Olanzapine Cipla (previously Olanzapine Neopharma) (olanzapine) — Cipla (EU) Limited
EMA withdrew Olanzapine Cipla (formerly Olanzapine Neopharma) in the EU; therapeutic areas include schizophrenia and bipolar disorder.